AstraZeneca advances scientific leadership in cardiovascular and renal diseases with over 60 abstracts collectively at ASN Kidney Week 2022 and AHA Scientific Sessions 2022
Depth and breadth of data underscore commitment to addressing areas of high unmet need in cardiorenal and rare nephrology diseases.AstraZeneca will present over 60 abstracts across its industry-leading Cardiovascular, Renal and Metabolism (CVRM) portfolio and from Alexion, AstraZeneca’s Rare Disease group, at the American Society of Nephrology (ASN) Kidney Week from 3-6 November 2022 and the American Heart Association (AHA) Scientific Sessions occurring 5-7 November 2022. With robust science across both medical congresses, AstraZeneca demonstrates its ambition to fundamentally transform